Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 11 art units • 13 examiners • 0 of 14 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
Chiesi Farmaceutici S.p.a. has 14 pending office actions in Biotechnology & Pharmaceuticals. The portfolio reaches 13 examiners and 11 art units, indicating a wide distribution of examination responsibility and technical settings. The difference between the action volume and examiner count shows that at least one examiner handles multiple pending matters.
ENGLISH, CONNOR KENNEDY is the busiest examiner, with 2 pending matters. That is the largest examiner-specific assignment in the profile, but it represents only part of the overall docket. Counsel should therefore combine centralized portfolio coordination with response plans adapted to the many examiner and art-unit contexts.
The 11 art-unit assignments provide a useful organizing structure for reviewing recurring claim, written-description, or prior-art issues where they arise. The examiner spread also makes deadline control and consistent disclosure positions important, since prosecution activity is distributed rather than concentrated in one relationship.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (7%) |
| §101 + other | 1 (7%) |
| §103 only | 3 (21%) |
| §112 only | 4 (29%) |
| Double-patenting + other | 2 (14%) |
| Multi-statute (no §101) | 3 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ENGLISH, CONNOR KENNEDY | 2 | 59.3% | +50.3% |
| BABSON, NICOLE PLOURDE | 1 | 46.7% | +33.7% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
| MURPHY, VICTORIA | 1 | 62.0% | +46.3% |
| ISLAM, MOHAMMAD K | 1 | 82.9% | +17.4% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282068 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | LEE, CHIHYI NMN | 26d |
| 18865906 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | BABSON, NICOLE PLOURDE | — |
| 18885921 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME | SEAMAN, D MARGARET M | — |
| 18844467 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18704036 | APPARATUS FOR ADMINISTERING MEDICAMENTS AND METHOD FOR MANAGING EXPIRY DATES OF A MEDICAMENT DISPENSER | ISLAM, MOHAMMAD K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283855 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | NOTTINGHAM, KYLE GREGORY | 5d |
| 18282068 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | LEE, CHIHYI NMN | 26d |
| 18631588 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS | ARNOLD, ERNST V | 30d |
| 18551942 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | GONZALEZ, LUISALBERTO | 48d |
| 18865906 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | BABSON, NICOLE PLOURDE | — |
| 18859618 | NEW CRYSTAL FORM OF A PDE4 INHIBITOR | ENGLISH, CONNOR KENNEDY | — |
| 18844467 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18728106 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ENGLISH, CONNOR KENNEDY | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1625 | 2 |
| 3785 | 2 |
| 1619 | 1 |
| 2857 | 1 |
| 1613 | 1 |
| 1621 | 1 |
| 1624 | 1 |
| 1628 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18865906 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | BABSON, NICOLE PLOURDE | 1619 | §103§112Other | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18859618 | NEW CRYSTAL FORM OF A PDE4 INHIBITOR | ENGLISH, CONNOR KENNEDY | 1629 | §112 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18885921 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME | SEAMAN, D MARGARET M | 1625 | §101§102§112 | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18844467 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102§103 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18728106 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18721184 | POWDER INHALER | MURPHY, VICTORIA | 3785 | §103 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18704036 | APPARATUS FOR ADMINISTERING MEDICAMENTS AND METHOD FOR MANAGING EXPIRY DATES OF A MEDICAMENT DISPENSER | ISLAM, MOHAMMAD K | 2857 | §101 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18631588 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS | ARNOLD, ERNST V | 1613 | §103DP | Final Rejection | 30d | Pending | Apr 10, 2024 |
| 18283855 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | NOTTINGHAM, KYLE GREGORY | 1621 | §112 | Final Rejection | 5d | Pending | Sep 25, 2023 |
| 18551942 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | GONZALEZ, LUISALBERTO | 1624 | §112 | Non-Final OA | 48d | Pending | Sep 22, 2023 |
| 18282068 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | LEE, CHIHYI NMN | 1628 | §102§103§112 | Non-Final OA | 26d | Pending | Sep 14, 2023 |
| 18203381 | Pharmaceutical Compositions and Methods for Stabilizing the Same | MEYERS, ELIZABETH ANNE | 1622 | §112DP | Non-Final OA | — | Pending | May 30, 2023 |
| 18030153 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | BASQUILL, SEAN M | 1614 | §103Other | Final Rejection | — | Pending | Apr 04, 2023 |
| 17801067 | PRESSURISED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | JANG, JAEICK | 3785 | §103 | Final Rejection | 12d | Pending | Aug 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChiesi Farmaceutici S.p.a. has 14 pending office actions as of October 2026, spread across 11 art units and 13 examiners.
Connor Kennedy English has the most, with 2 of Chiesi Farmaceutici S.p.a.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
